The Global Market for Pig Health and Nutrition Products
PRODUCTS
MARKETS
Animal Pharm Reports provides you with an extensive review of the major markets for pig health and nutrition products. It will enable you to access up-to-date information on the trends, products and key companies in each country and product sector.
The Global Market for Pig Health and Nutrition Products will:
PUBLISHED: JANUARY 2001
REFERENCE: SR201E
HARDCOPY PRICE: £395/$830/¥95,000
PAGES: 121
ELECTRONIC LICENCE*: £2,370/$4,980/¥569,000
* Electronic price quoted is for a Global unlimited sites/users licence. Single site and multiple site electronic licences are also available.
For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]
CONTENTS
LIST OF TABLES
LIST OF FIGURES
EXECUTIVE SUMMARY
ABBREVIATIONS
1 PIG DISEASES (pages 22)
1.1 Bacterial diseases
1.1.1 Pasteurellosis
1.1.2 Bacterial pneumonia or pleuropneumonia
1.1.3 Atrophic rhinitis
1.1.4 Escherichia coli infections
1.1.5 Clostridium perfringens
1.1.6 Salmonellosis
1.1.7 Porcine enteropathies or ileitis
1.1.8 Porcine streptococcal infections
1.1.9 Staphylococcal infections
1.1.10 Erysipelas
1.1.11 Gl�sser's disease
1.1.12 Porcine brucellosis
1.1.13 Mastitis Metritis Agalactia syndrome
1.2 Mycoplasmal infections
1.2.1 Mycoplasmal pneumonia
1.2.2 Mycoplasmal arthritis
1.3 Spirochete diseases
1.3.1 Swine dysentery
1.3.2 Leptospirosis
1.3.3 Porcine colonic spirochaetosis
1.4 Viral diseases
1.4.1 Classical swine fever
1.4.2 African swine fever
1.4.3 Swine influenza
1.4.4 Aujeszky's disease
1.4.5 Transmissible gastroenteritis
1.4.6 Rotaviral enteritis
1.4.7 Encephalomyocarditis
1.4.8 Foot and mouth disease
1.4.9 Swine vesicular disease
1.4.10 Porcine parvovirus
1.4.11 Porcine reproductive and respiratory syndrome
1.4.12 Post-weaning multisystemic wasting syndrome
1.4.13 Porcine dermatitis and nephropathy syndrome
1.4.14 Nipah
1.5 Major pig parasites
1.5.1 Endoparasites
1.5.1.1 Ascaris suum
1.5.1.2 Hyostrongylus rubidus
1.5.1.3 Strongyloides ransomi
1.5.1.4 Oesophagostomum spp
1.5.1.5 Trichuris suis
1.5.1.6 Stephanurus dentatus
1.5.1.7 Metastrongylus apri
1.5.1.8 Trichinella spiralis
1.5.1.9 Eimeria spp, Cryptosporidium spp and Isospora spp
1.5.1.10 Taenia solium
1.5.2 Ectoparasites
1.5.2.1 Lice
1.5.2.2 Mites
1.5.2.3 Ticks
2 PRODUCT PROFILES (23 pages)
2.1 Nutritional feed additives
2.1.1 Vitamins
2.1.1.1 Vitamin A
2.1.1.2 (-carotene
2.1.1.3 Vitamin D
2.1.1.4 Vitamin E
2.1.1.5 Vitamin K
2.1.1.6 Vitamin B1
2.1.1.7 Vitamin B2
2.1.1.8 Vitamin B6
2.1.1.9 Vitamin B12
2.1.1.10 Biotin (vitamin H)
2.1.1.11 Pantothenic acid
2.1.1.12 Nicotinic acid
2.1.1.13 Choline
2.1.1.14 Vitamin C
2.1.2 Amino acids
2.1.3 Organic acids
2.1.3.1 Propionic acid
2.1.3.2 Formic acid
2.1.4 Enzymes
2.2 Medicated feed additives
2.2.1 Performance enhancers
2.2.1.1 Anti-infective performance enhancers
2.2.1.2 Probiotics
2.2.1.3 Hormonal performance enhancers
2.2.2 Medicinal feed additives
2.2.2.1 Anti-infective pre-mixes
2.2.2.2 Antiparasitic pre-mixes
2.3 Pharmaceutical anti-infectives
2.3.1 Aminoglycosides
2.3.2 Cephalosporins
2.3.3 Chloramphenicol and related compounds
2.3.4 Macrolides, pleuromutilins and lincosamides
2.3.5 Penicillins
2.3.6 Fluoroquinolones
2.3.7 Sulphonamides
2.3.8 Tetracyclines
2.4 Biologicals
2.4.1 Atrophic rhinitis
2.4.2 Aujeszky's disease
2.4.3 Classical swine fever
2.4.4 Enteric colibacillosis
2.4.5 Mycoplasmal pneumonia
2.4.6 Pleuropneumonia
2.4.7 Porcine reproductive and respiratory syndrome
2.4.8 Salmonellosis
2.4.9 Swine erysipelas
2.4.10 Transmissible gastroenteritis
2.4.11 New developments
2.5 Non-oral antiparasitics
2.5.1 Endoparasitics
2.5.2 Ectoparasitics
2.5.2.1 Amitraz
2.5.2.2 Organophosphates
2.5.2.3 Pyrethrins
2.5.3 Endectocides
2.5.3.1 Doramectin (Dectomax - Pfizer)
2.5.3.2 Ivermectin (Ivomec - Merial)
2.6 Other products
2.6.1 Altrenogest (Regumate Porcine -HR Vet (now Intervet))
2.6.2 Gonadotrophins (PG600 - Intervet)
2.6.3 Prostaglandins (Iliren - HR Vet; Planate - SPAH; Dinolytic/Lutalyse - Pharmacia Corp)
2.6.4 Oxitocin
2.6.5 Azaperon (Stresnil - Janssen)
2.6.6 Metamizol (Novalgin - HR Vet)
2.6.7 Hyoscine N-butylbromide (Buscopan - Boehringer Ingelheim)
2.6.8 Bromhexin (Bisolvon - Boehringer Ingelheim)
2.6.9 Dexamethasone
3 PIG MARKETS (33 pages)
3.1 The world market for pig products
3.2 Pig population and pig meat production
3.3 Country profiles
3.3.1 North America
3.3.1.1 Canada
3.3.1.2 US
3.3.2 Latin America
3.3.2.1 Argentina
3.3.2.2 Brazil
3.3.2.3 Mexico
3.3.2.4 Other Latin American countries
3.3.3 European Union
3.3.3.1 Belgium
3.3.3.2 Denmark
3.3.3.3 France
3.3.3.4 Germany
3.3.3.5 Italy
3.3.3.6 The Netherlands
3.3.3.7 Spain
3.3.3.8 UK
3.3.4 Central Europe and CIS
3.3.5 Asia
3.3.5.1 China
3.3.5.2 Japan
3.3.5.3 Other Asian countries
3.3.6 Australia
3.4 World issues in pig production
3.4.1 Disease eradication
3.4.2 Waste
3.4.3 Animal welfare
3.4.4 Resistance against anti-infectives
3.4.5 Harmonisation of the registration of veterinary products
3.4.6 Future prospects
4 COMPANY PROFILES (22 pages)
4.1 Alpharma
4.1.1 Products
4.1.2 Research and development
4.2 Aventis Animal Nutrition
4.2.1 Products
4.3 BASF
4.3.1 Products
4.4 Bayer
4.4.1 Products
4.4.2 Research and development
4.5 Boehringer Ingelheim
4.5.1 Products
4.5.2 Research and development
4.6 Degussa-H�ls
4.6.1 Products
4.7 Elanco
4.7.1 Products
4.8 Fort Dodge
4.8.1 Products
4.9 Hoffmann-La Roche
4.9.1 Products
4.10 Intervet
4.10.1 Products
4.11 Merial
4.11.1 Products
4.11.2 Research and development
4.12 Novartis
4.12.1 Products
4.13 Pfizer
4.13.1 Product
4.14 Pharmacia
4.14.1 Products
4.15 Schering-Plough Animal Health
4.15.1 Products
LIST OF TABLES
Table 1.1 Common agents that cause respiratory diseases
Table 1.2 Common agents that cause intestinal infections
Table 1.3 Common pig endoparasites
Table 1.4 Common pig ectoparasites
Table 2.1 Important amino acids for pig feed
Table 2.2 Therapeutic efficacy of common in-feed anti-infectives
Table 2.3 Therapeutic efficacy of common in-feed anthelmintics
Table 2.4 Therapeutic efficacy of common injectable anti-infectives
Table 3.1 Global pig stocks and pig meat production, 1999
Table 3.2 Development pig stocks by country, 1995-1999 (million head)
Table 4.1 Alpharma's main products for use in pigs
Table 4.2 AAN's main products for use in pigs
Table 4.3 BASF's main products for use in pigs
Table 4.4 Bayer's main products for use in pigs
Table 4.5 Boehringer Ingelheim's main products for use in pigs
Table 4.6 Degussa-H�ls' main products for use in pigs
Table 4.7 Elanco's main products for use in pigs
Table 4.8 Fort Dodge's main products for use in pigs
Table 4.9 Hoffmann-La Roche's main products for use in pigs
Table 4.10 Intervet's main products for use in pigs
Table 4.11 Pig products acquired with the purchase of HR Vet
Table 4.12 Merial's main products for use in pigs
Table 4.13 Novartis' main products for use in pigs
Table 4.14 Pfizer's main products for use in pigs
Table 4.15 Pharmacia's main products for use in pigs
Table 4.16 Schering-Plough Animal Health's main products for use in pigs
LIST OF FIGURES
Figure 3.1 World animal health market by region, 1999
Figure 3.2 World animal health market by species, 1999
Figure 3.3 Use of animal health products in pigs, 1999
Figure 3.4 Distribution of the global pig production, 1999
Figure 3.5 Canadian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.6 US pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.7 Argentinian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.8 Brazilian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.9 Mexican pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.10 Distribution of pig population in the EU by country, 1999 (million head)
Figure 3.11 European Union pig meat production, 1995-1999 ('000 tonnes)
Figure 3.12 Belgian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.13 Danish pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.14 French pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.15 German pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.16 Italian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.17 Dutch pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.18 Spanish pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.19 UK pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.20 Polish pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.21 Russian pig meat production, export and import, 1995-1999 ('000 tonnes)
Figure 3.22 Chinese pig meat production, export and import, 1995-1999 ('000)
Figure 3.23 Japanese pig meat production, export and import, 1995-1999 ('000)
Figure 3.24 Australian pig meat production, export and import, 1995-1999 ('000 tonnes)
SUMMARISED EXECUTIVE SUMMARY
The global market for pig health and nutrition products had, in 1999, a total value of $4.47 billion making the pig sector the second largest after cattle. This reflects an increase of approximately 5.5% on the according 1996 figure, despite the fact that the sector has had to face serious difficulties during that period of time.
Driven by increasing competition, the pig industry continues to move in the direction of intensive pig production, where profit margins closely depend on the performance and the efficiency of the enterprise. Along with the continuance of intensive pig farming and production, come inevitable changes in disease patterns and the impact they can have. On a global level, this is reflected, for example, in the decreasing significance of pig parasites and in the increasing susceptibility of pig herds to respiratory diseases.
Both intensive pig production and extensive cross border trade of live pigs facilitate the worldwide spread of porcine respiratory and reproductive syndrome (PRRS). The resulting production losses have been colossal - as has been the economic success of PRRS vaccines, once they were made available. Other respiratory diseases are becoming equally as restricting to pig production, such as mycoplasmal pneumonia, pasteurellosis, swine influenza and pleuropneumonia. There are also other, new diseases, already emerging in the sector.
Regional eradication programmes of other porcine diseases are in progress, and once completed could earn significant savings in terms of reduced medication costs. The downside is, of course, the vulnerability of a national pig herd to the return of a previously eliminated disease, where non-vaccination policies have been put in place. The repeated outbreaks of classical swine fever (CSF) in countries of the EU over the past years have been a prime example of this threat. Another disease that repeatedly causes economical damage to certain regions is foot and mouth disease (FMD).
The categories of health and nutrition products for use in pigs, which are dealt with in this report, are nutritional feed additives, medicated feed additives, non-oral antiparasitics, pharmaceutical anti-infectives, biologicals and others.
© PJB Publications Ltd. 2000 All rights reserved. |